- Home
- NTIP vs BCAB Comparison
NTIP vs BCAB Comparison
Compare NTIP & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- BCAB
- Stock Information
- Founded
- NTIP 1990
- BCAB 2007
- Country
- NTIP United States
- BCAB United States
- Employees
- NTIP N/A
- BCAB N/A
- Industry
- NTIP Multi-Sector Companies
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- NTIP Miscellaneous
- BCAB Health Care
- Exchange
- NTIP Nasdaq
- BCAB Nasdaq
- Market Cap
- NTIP 32.9M
- BCAB 27.0M
- IPO Year
- NTIP 1998
- BCAB 2020
- Fundamental
- Price
- NTIP $1.38
- BCAB $0.41
- Analyst Decision
- NTIP
- BCAB Buy
- Analyst Count
- NTIP 0
- BCAB 2
- Target Price
- NTIP N/A
- BCAB $5.00
- AVG Volume (30 Days)
- NTIP 15.2K
- BCAB 834.0K
- Earning Date
- NTIP 03-07-2025
- BCAB 03-25-2025
- Dividend Yield
- NTIP 7.25%
- BCAB N/A
- EPS Growth
- NTIP N/A
- BCAB N/A
- EPS
- NTIP N/A
- BCAB N/A
- Revenue
- NTIP $1,881,000.00
- BCAB $11,000,000.00
- Revenue This Year
- NTIP N/A
- BCAB N/A
- Revenue Next Year
- NTIP N/A
- BCAB N/A
- P/E Ratio
- NTIP N/A
- BCAB N/A
- Revenue Growth
- NTIP 129.39
- BCAB N/A
- 52 Week Low
- NTIP $1.22
- BCAB $0.38
- 52 Week High
- NTIP $2.25
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- NTIP 50.88
- BCAB 32.49
- Support Level
- NTIP $1.34
- BCAB $0.42
- Resistance Level
- NTIP $1.42
- BCAB $0.50
- Average True Range (ATR)
- NTIP 0.03
- BCAB 0.05
- MACD
- NTIP 0.00
- BCAB 0.02
- Stochastic Oscillator
- NTIP 50.00
- BCAB 20.97
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.